{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:39:51Z","timestamp":1785173991541,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22zf0127001"],"award-info":[{"award-number":["JP22zf0127001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23zf0127001"],"award-info":[{"award-number":["JP23zf0127001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0210168"],"award-info":[{"award-number":["JP22ek0210168"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Amplification of <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content> is a major oncogenic driver of high\u2010risk neuroblastomas. We previously developed <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002, a <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010selective pyrrole\u2010imidazole polyamide conjugated to a <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> alkylating agent. Administration of <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 to <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010amplified (<jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010amp) neuroblastoma cells triggered the activation of <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> damage responses. Here, we demonstrated that among the <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> damage response inhibitors, ataxia telangiectasia and Rad3\u2010related (<jats:styled-content style=\"fixed-case\">ATR<\/jats:styled-content>) inhibitors synergized with <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 to suppress <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> repair\u2010related genes and induce apoptosis in <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010amp neuroblastoma cells. A synergistic antitumor effect was verified in an <jats:styled-content style=\"fixed-case\">SK<\/jats:styled-content>\u2010N\u2010<jats:styled-content style=\"fixed-case\">BE<\/jats:styled-content>(2) xenograft mouse model, in which the combined use of <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 and <jats:styled-content style=\"fixed-case\">ATR<\/jats:styled-content> inhibitor at low doses significantly inhibited tumor progression. Notably, <jats:styled-content style=\"fixed-case\">SK<\/jats:styled-content>\u2010N\u2010<jats:styled-content style=\"fixed-case\">BE<\/jats:styled-content>(2) and <jats:styled-content style=\"fixed-case\">SK<\/jats:styled-content>\u2010N\u2010<jats:styled-content style=\"fixed-case\">DZ<\/jats:styled-content> cells, which showed <jats:styled-content style=\"fixed-case\">ATM<\/jats:styled-content> activation after <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 treatment, exhibited high sensitivity to the combined treatment of <jats:styled-content style=\"fixed-case\">ATR<\/jats:styled-content> inhibitors. Comprehensive analysis of the gene expression profiles revealed that the combination treatment upregulated apoptosis\u2010related pathways and downregulated <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> repair\u2010related pathways. After the combined treatment of <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 and <jats:styled-content style=\"fixed-case\">ATR<\/jats:styled-content> inhibitor, <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010amp cells showed less <jats:styled-content style=\"fixed-case\">FISH<\/jats:styled-content> probe signal and <jats:styled-content style=\"fixed-case\">mRNA<\/jats:styled-content> expression of <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>, which was accompanied by an increase in <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> damage markers in the genomic region of <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>, highlighting that <jats:styled-content style=\"fixed-case\">ATR<\/jats:styled-content> inhibitors synergize with <jats:styled-content style=\"fixed-case\">CCC<\/jats:styled-content>\u2010002 and play a crucial role in the development of a novel <jats:styled-content style=\"fixed-case\">MYCN<\/jats:styled-content>\u2010targeting therapy for <jats:styled-content style=\"fixed-case\"><jats:italic>MYCN<\/jats:italic><\/jats:styled-content>\u2010amp neuroblastoma.<\/jats:p>","DOI":"10.1111\/cas.70043","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:45:32Z","timestamp":1741711532000},"page":"1691-1702","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["<scp>ATR<\/scp> Inhibition Synergizes With Alkylating <scp>PI<\/scp> Polyamide Targeting <scp><i>MYCN<\/i><\/scp> by Suppressing <scp>DNA<\/scp> Repair in <scp><i>MYCN<\/i><\/scp>\u2010Amplified Neuroblastoma"],"prefix":"10.1111","volume":"116","author":[{"given":"Xiaoyi","family":"Lai","sequence":"first","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"},{"name":"Graduate School of Medical and Pharmaceutical Sciences, Chiba University  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-8940","authenticated-orcid":false,"given":"Hiroyuki","family":"Yoda","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Qiao","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"},{"name":"Graduate School of Medical and Pharmaceutical Sciences, Chiba University  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kida","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-6742","authenticated-orcid":false,"given":"Keizo","family":"Takenaga","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Koshikawa","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-6721","authenticated-orcid":false,"given":"Atsushi","family":"Takatori","sequence":"additional","affiliation":[{"name":"Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624079"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1382"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29706"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010018\u20100924\u2010z"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.40"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014266"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201018\u20101198"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150794"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2018.08.022"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27329"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246215"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010020\u201000171\u20108"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.MCR\u201010\u20100227"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907763107"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120334"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41021\u2010020\u20100148\u20101"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11791"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109341"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv673"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep38873"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/children5080107"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201021\u20102997"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx062"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010023\u201010"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq011"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28336"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2016.65667"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201013\u20100136"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201027"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051095"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010021\u201002003\u20100"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210707"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/416560a"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl619"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7706"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.03.001"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5027"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010019\u201000873\u20106"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806308105"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500964c"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91788"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T02:06:11Z","timestamp":1748829971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cas.70043"],"URL":"https:\/\/doi.org\/10.1111\/cas.70043","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}